Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;30(5):e13701.
doi: 10.1111/srt.13701.

Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis

Lei Yan  1 , Yuquan Shi  1 , Chunye Wu  1 , Yuan Li  1
Affiliations

Multivariate logistic regression analysis of poor prognosis of dermatomyositis and clinical value of ferritin/Kl-6 in predicting prognosis

Lei Yan et al. Skin Res Technol. 2024 May.

Abstract

Background: Dermatomyositis (DM) is a rare inflammatory disease. Our research focuses on predicting poor prognosis in DM patients and evaluating the prognostic significance of ferritin and Salivary Sugar Chain Antigen-6 (KL-6) through multivariate logistic regression analysis.

Methods: Between February 2018 and April 2020, 80 DM patients at our hospital were categorized into MDA5 positive (n = 20) and negative (n = 60) groups. We conducted multivariate logistic regression to determine DM's poor prognosis risk factors and evaluate ferritin/KL-6's predictive value for prognosis.

Results: Analysis showed no gender, age, body mass index (BMI), or lifestyle (smoking, drinking) differences, nor in dyspnea, muscle weakness, skin ulcers, and acetylcysteine treatment effects (p > 0.05). Significant differences emerged in arrhythmias, interstitial pneumonia, C-reactive protein, albumin, and lactate dehydrogenase levels (p < 0.05). Before treatment, differences were negligible (p > 0.05), but post-treatment, serum KL-6 and ferritin levels dropped. MDA5 positive patients had elevated serum KL-6 and ferritin levels than survivors (p < 0.05), with a strong correlation to DM. Combined diagnosis using serum KL-6 and ferritin for DM prognosis showed area under curves of 0.716 and 0.634, significantly outperforming single-index diagnoses with an area under curve (AUC) of 0.926 (p < 0.05).

Conclusion: Serum KL-6 and ferritin show marked abnormalities in DM, useful as indicators for evaluating polymyositis and DM conditions. However, the study's small sample size is a drawback. Expanding the sample size is essential to monitor serum KL-6 and ferritin changes in DM patients under treatment more closely, aiming to improve clinical assessment and facilitate detailed research.

Keywords: Kl‐6; dermatomyositis; ferritin; multivariate logistic regression analysis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
ROC curve of serum KL‐6 index in predicting the prognosis of dermatomyositis.
FIGURE 2
FIGURE 2
ROC curve of the prognostic value of serum ferritin in dermatomyositis.
FIGURE 3
FIGURE 3
ROC curve of combined diagnosis of serum KL‐6 and ferritin in predicting the prognosis of dermatomyositis.
See this image and copyright information in PMC

References

    1. Li X, Liu Y, Cheng L, et al. Roles of biomarkers in anti‐MDA5‐positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease. J Clin Lab Anal. 2022;36(11):e24726. - PMC - PubMed
    1. Yang L, Ye T, Liu H, Huang C, Tian W, Cai Y. A case of Anti‐MDA5‐Positive dermatomyositis after inactivated COVID‐19 vaccine. J Eur Acad Dermatol Venereol. 2023;37(2):e127‐e129. - PMC - PubMed
    1. Huang W, Ren F, Chen D, Wang Z, Tang L. The value of metagenomic next‐generation sequencing in bronchoalveolar lavage fluid samples of anti‐MDA5‐positive dermatomyositis patients. Rheumatology. 2023;62(3):e36‐e38. - PubMed
    1. Jia F, Jiang S, Zhang J, Fu Q, Zhang X, Ye Y. A preliminary study of frequency and clinical relevance of cytotoxic peripheral CD4 and CD8 T cells in patients with Anti‐MDA5 positive dermatomyositis. Rheumatol Immunol Res. 2022;3(3):136‐142. - PMC - PubMed
    1. He S, Zhou Y, Fan C, et al. Differences in sex‐and age‐associated mortality in patients with anti‐MDA5‐positive dermatomyositis. Modern Rheumatology. 2023;33(5):975‐981. - PubMed